Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.58 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25058882 | 0.88 | HDAC1 (0.79) | HDAC1HDAC6TNFNOD2NOD1 | |
| SCHEMBL12895811 | 0.86 | HDAC1 (0.76) | HDAC1HDAC6TNFNOD2NOD1 | |
| SCHEMBL20548055 | 0.83 | HDAC1 (0.88) | HDAC1HDAC6HDAC8HDAC4 | |
| SCHEMBL26159154 | 0.81 | HDAC1 (1.00) | HDAC1HDAC6TNFNOD2NOD1 | |
| SCHEMBL25058892 | 0.80 | HDAC1 (0.66) | HDAC1HDAC6KCNH2 | |
| SCHEMBL26159142 | 0.79 | HDAC1 (0.65) | HDAC1HDAC6HDAC8 | |
| SCHEMBL3148037 | 0.79 | HDAC1 (0.65) | HDAC1HDAC6KCNH2 | |
| SCHEMBL23950270 | 0.79 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC4 | |
| SCHEMBL30053304 | 0.79 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC4 | |
| SCHEMBL23950268 | 0.79 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4137483-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Zhongze Therapeutics, Co. Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| CN-113527206-B | Benzoazaheterocycle compound, preparation method and application thereof | 上海中泽医药科技有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-113527206-A | Benzoazaheterocycle compound, preparation method and application thereof | 上海中泽医药科技有限公司 | 2021-10-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HDAC11, HDAC1, HDAC6 | HDAC1 2/4885HDAC6 3/4885TNF 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.